Jefferies Reiterates Buy Rating on Cara Therapeutics (CARA); 'New Korsuva "Add-on Payment" Extended to 2027'
Tweet Send to a Friend
(Updated - June 27, 2023 9:42 AM EDT)
Jefferies analyst Dennis Ding reiterated a Buy rating and $18.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Dennis Ding reiterated a Buy rating and $18.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
